Ambitree India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 40.01%
(FY 2023)
- Profit -2.55%
(FY 2023)
- Ebitda -57.10%
(FY 2023)
- Net Worth 22.36%
(FY 2023)
- Total Assets -33.82%
(FY 2023)
About Ambitree India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Meenu Khaneja and Lakshay Khanna serve as directors at the Company.
- CIN/LLPIN
U24290DL2019PTC349195
- Company No.
349195
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ambitree India Private Limited offer?
Ambitree India Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Cardiovascular Drugs & Medication, Kidney Drugs, Pharmaceutical Capsules, Anti Infective Drugs & Medicines, Antibiotic Injection, Arthritic Drugs.
Who are the key members and board of directors at Ambitree India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meenu Khaneja  | Director | 26-Apr-2019 | Current |
| Lakshay Khanna | Director | 26-Apr-2019 | Current |
Financial Performance of Ambitree India.
Ambitree India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.01% increase. The company also saw a slight decrease in profitability, with a 2.55% decrease in profit. The company's net worth Soared by an impressive increase of 22.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ambitree India?
In 2023, Ambitree India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Shree Gobind Pharmaceuticals Private LimitedActive 18 years 10 months
Meenu Khaneja is a mutual person
- Shree Radhey Gobind Pharmaceuticals Private LimitedActive 12 years 5 days
Meenu Khaneja is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ambitree India?
Unlock and access historical data on people associated with Ambitree India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ambitree India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ambitree India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
